ICU Medical (ICUI) Q4 2015 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2015 earnings summary
6 Nov, 2026Executive summary
FY15 described as a record year for revenue, gross margin and adjusted EBITDA; direct-business growth, cost improvements and investment aimed to diversify revenue and profits from a concentrated customer.
Priorities included new product launches, global revenue growth and disciplined capital deployment; management expected substantially improved earnings and cash flow in 2016.
Financial highlights
Revenue was $341.7M vs. $309.3M in 2014; constant-currency revenue was $350.6M, up $41.3M YoY.
Net income rose to $45.0M from $26.3M; diluted EPS was $2.73 vs. $1.68.
Operating income was $68.6M vs. $39.0M; operating cash flow was $54.9M vs. $60.6M.
Fourth-quarter revenue was $90.4M, gross profit $48.3M, net income $5.5M and diluted EPS $0.33.
Outlook and guidance
Management expected substantially improved earnings and cash flow in 2016; the largest customer was expected to represent a record-low share of revenue, though exposure remained significant.
2016 capital expenditures estimated at $18M–$20M for US and Mexico manufacturing equipment, molds, IT and Mexico facility expansion.
Slovakia facility closure and product transfer to Mexico expected to finish in H2 2016; the board expected closure completion in Q3 2016.
SwabCap expected to have minimal EPS impact in its first year, with a greater return on invested capital thereafter.
Latest events from ICU Medical
- Record revenue and cash flow, led by infusion and oncology, offset critical care pressure.ICUI
Q4 2011 - Record FY09 revenue and earnings accompanied a major shift to direct critical care sales.ICUI
Q4 2009 - Custom and direct-channel growth lifted 2010 results, while Hospira concentration remains a key risk.ICUI
Q4 2010 - Record revenue and stronger margins, offset by lower earnings and critical care sales.ICUI
Q4 2012 - Normalized IV Solutions demand cut FY19 revenue, while cash and integration savings supported resilience.ICUI
Q4 2019 - Record FY16 growth funded an infusion transformation, with integration the near-term test.ICUI
Q4 2016 - HIS expanded the portfolio, but integration costs drove a FY2017 operating loss.ICUI
Q4 2017 - Integration neared completion as cash grew, but reported earnings absorbed heavy one-time charges.ICUI
Q4 2018 - Infusion Systems growth and record operating cash flow cushioned pandemic-driven weakness elsewhere.ICUI
Q4 2020